Phase II Study of Atezolizumab and Bevacizumab Combination Therapy for Patients with Advanced Hepatocellular Carcinoma Previously Treated with Lenvatinib
Cancers · 16.01.2025 · 17 (2) · 278
DOI: 10.3390/cancers17020278 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 16.01.2025. Verfasst von Takeshi Terashima und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Kanazawa University Hospital, Kanazawa 920-8641, Ishikawa, Japan. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Atezolizumab and bevacizumab combination therapy has been established as a standard of care for first-line treatment; however, its efficacy and safety have not been fully evaluated for patients previously treated with systemic therapy.
Methods
In this phase II trial, patients with advanced hepatocellular carcinoma previously treated with lenvatinib were enrolled to receive a dose of 1,200 mg of atezolizumab and 15 mg/kg of bevacizumab every 3 weeks. The primary endpoint was progression-free survival. The secondary endpoints included overall survival, objective response rate, disease control rate, subsequent therapy, and frequency of adverse events. The threshold and expected progression-free survival were 3 and 6.8 months, respectively. Considering a one-sided significance level of 0.05 and a statistical power of 80%, the minimum required sample size was 26 patients.
Results
The median progression-free survival from the start of treatment was 9.70 [90% confidence interval, 5.10–14.24] months, and the lower limit of the 90% CI was above the predefined threshold. The objective response and disease control rates were 34.6% and 73.1%, respectively. Sixteen patients (61.5%) received subsequent therapies, and the median overall survival was 17.23 [90% confidence interval, 13.18–27.85] months. Severe adverse events, adverse events leading to treatment delays, and adverse events leading to treatment discontinuation occurred in eight (30.8%), fourteen (53.8%), and five (19.2%) patients, respectively, and no treatment-related deaths occurred.
Conclusions
Atezolizumab and bevacizumab combination therapy is effective and can safely be administered to patients with advanced HCC previously treated with lenvatinib.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Kanazawa University Hospital, Kanazawa 920-8641, Ishikawa, Japan.
- Department of Nephrology, Faculty of Medical Sciences, University of Fukui, Fukui 910-1104, Fukui, Japan.
ORCID-Profile: Takeshi Terashima, Akihiro Seki, Hidetoshi Nakagawa, Kouki Nio, Tadashi Toyama, Taro Yamashita
Zitieren
APA
Terashima, T., Kido, H., Takata, N., Hayashi, T., Seki, A., Nakagawa, H., Nio, K., Toyama, T., Iida, N., Yamada, S., Shimakami, T., Takatori, H., Arai, K., Yamashita, T., Mizukoshi, E., & Yamashita, T. (2025). Phase II Study of Atezolizumab and Bevacizumab Combination Therapy for Patients with Advanced Hepatocellular Carcinoma Previously Treated with Lenvatinib. Cancers, 17(2), 278. https://doi.org/10.3390/cancers17020278
Vancouver
Terashima T, Kido H, Takata N, Hayashi T, Seki A, Nakagawa H, et al. Phase II Study of Atezolizumab and Bevacizumab Combination Therapy for Patients with Advanced Hepatocellular Carcinoma Previously Treated with Lenvatinib. Cancers. 2025;17(2):278. doi:10.3390/cancers17020278
BibTeX
@article{Terashima2025,
author = {Terashima, Takeshi and Kido, Hidenori and Takata, Noboru and Hayashi, Tomoyuki and Seki, Akihiro and Nakagawa, Hidetoshi and Nio, Kouki and Toyama, Tadashi and Iida, Noriho and Yamada, Shinya and Shimakami, Tetsuro and Takatori, Hajime and Arai, Kuniaki and Yamashita, Tatsuya and Mizukoshi, Eishiro and Yamashita, Taro},
title = {Phase II Study of Atezolizumab and Bevacizumab Combination Therapy for Patients with Advanced Hepatocellular Carcinoma Previously Treated with Lenvatinib},
journal = {Cancers},
year = {2025},
volume = {17},
number = {2},
pages = {278},
doi = {10.3390/cancers17020278}
}
EUVIMED